NO20085032L - Aminotiazoler og deres anvendelser - Google Patents

Aminotiazoler og deres anvendelser

Info

Publication number
NO20085032L
NO20085032L NO20085032A NO20085032A NO20085032L NO 20085032 L NO20085032 L NO 20085032L NO 20085032 A NO20085032 A NO 20085032A NO 20085032 A NO20085032 A NO 20085032A NO 20085032 L NO20085032 L NO 20085032L
Authority
NO
Norway
Prior art keywords
aminothiazoles
relief
therapy
diseases
useful
Prior art date
Application number
NO20085032A
Other languages
English (en)
Inventor
Matthew J Lamarche
Simon Bushell
Michael A Patane
Lewis Whitehead
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20085032(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20085032L publication Critical patent/NO20085032L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Det beskrives organiske forbindelser som er nyttige ved terapi, prevensjon og/eller lindring av sykdommer.
NO20085032A 2006-05-31 2008-12-02 Aminotiazoler og deres anvendelser NO20085032L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80969306P 2006-05-31 2006-05-31
PCT/US2007/012768 WO2007142986A2 (en) 2006-05-31 2007-05-30 Aminothiazole derivatives and their uses as antibacterial agents

Publications (1)

Publication Number Publication Date
NO20085032L true NO20085032L (no) 2008-12-16

Family

ID=38645676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085032A NO20085032L (no) 2006-05-31 2008-12-02 Aminotiazoler og deres anvendelser

Country Status (31)

Country Link
US (2) US7851439B2 (no)
EP (2) EP2322536A3 (no)
JP (1) JP5351014B2 (no)
KR (1) KR101061658B1 (no)
CN (2) CN102399260B (no)
AR (1) AR060977A1 (no)
AU (1) AU2007255025B2 (no)
BR (1) BRPI0711885A2 (no)
CA (1) CA2650133A1 (no)
CL (1) CL2007001542A1 (no)
CR (1) CR10430A (no)
DK (1) DK2044101T3 (no)
EC (1) ECSP088922A (no)
ES (1) ES2441993T3 (no)
HR (1) HRP20140055T1 (no)
IL (1) IL194880A (no)
MA (1) MA30485B1 (no)
MX (1) MX2008015216A (no)
MY (1) MY146920A (no)
NO (1) NO20085032L (no)
NZ (1) NZ572154A (no)
PE (2) PE20080103A1 (no)
PL (1) PL2044101T3 (no)
PT (1) PT2044101E (no)
RU (1) RU2450015C2 (no)
SI (1) SI2044101T1 (no)
TN (1) TNSN08496A1 (no)
TW (2) TW201107337A (no)
UA (1) UA95627C2 (no)
WO (1) WO2007142986A2 (no)
ZA (1) ZA200808449B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080103A1 (es) * 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
WO2008082562A2 (en) * 2006-12-20 2008-07-10 Novartis Ag Aminothiazole macrocycles, their use as antibacterial compounds and processes for their production
AU2008258639B2 (en) 2007-06-04 2012-07-05 Novartis Ag Macrocycles and their uses
AU2012261611B2 (en) * 2007-12-12 2014-05-15 Novartis Ag Aminothiazoles and their uses
CA2708793C (en) * 2007-12-12 2016-06-21 Novartis Ag Aminothiazoles and their uses
WO2014167371A1 (en) * 2013-04-12 2014-10-16 Naicons S.C.A.R.L. Analogs of the antibiotic aminothiazole ge2270
CN106366168B (zh) * 2016-08-26 2020-09-15 上海交通大学 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN113219078B (zh) * 2021-03-25 2022-12-16 广东产品质量监督检验研究院（国家质量技术监督局广州电气安全检验所、广东省试验认证研究院、华安实验室） 一种生活用纸制品中17种有机抗菌剂快速筛查方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202241A (en) 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
ES2066914T3 (es) 1989-07-04 1995-03-16 Lepetit Spa Factores a1, a2, a3 y h del antibiotico ge 2270.
DK0451486T3 (da) 1990-03-08 1995-05-08 Lepetit Spa Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T
IL100572A (en) * 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DE69224497T2 (de) 1991-08-30 1998-07-02 Biosearch Italia Spa Faktor C2a des Antibiotikums CE 2270
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
DE69317058T2 (de) 1992-12-22 1998-06-10 Biosearch Italia Spa Die antibiotika ge 37468 a, b und c
WO1996014427A1 (en) * 1994-11-08 1996-05-17 Gruppo Lepetit S.P.A. Microbial transformation process for obtaining antibiotic ge 2270 factor d¿2?
ATE165101T1 (de) 1995-02-07 1998-05-15 Biosearch Italia Spa Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
JP3518606B2 (ja) 1995-02-07 2004-04-12 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ Ｇｅ２２７０及びｇｅ２２７０−様抗生物質の塩基性オキサゾリン−アミド誘導体
EP0880541B1 (en) 1996-02-14 2003-01-15 Biosearch Italia S.p.A. Derivatives of antibiotic ge2270 factors
JPH1059997A (ja) * 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
DK1553967T3 (da) * 2002-06-17 2011-08-29 Naicons S C A R L Anvendelse af et amidderivat af GE 2270 faktor A3 til behandling af acne
AU2005327139A1 (en) 2004-09-22 2006-08-17 Merck & Co., Inc. Antibiotic compound
PE20080103A1 (es) 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
CA2708793C (en) * 2007-12-12 2016-06-21 Novartis Ag Aminothiazoles and their uses

Also Published As

Publication number Publication date
EP2322536A3 (en) 2011-11-30
RU2008150785A (ru) 2010-07-10
MY146920A (en) 2012-10-15
BRPI0711885A2 (pt) 2012-03-06
IL194880A (en) 2015-02-26
HRP20140055T1 (hr) 2014-02-14
ZA200808449B (en) 2014-12-23
CN102399260A (zh) 2012-04-04
HK1127614A1 (en) 2009-10-02
MX2008015216A (es) 2008-12-12
JP2009538914A (ja) 2009-11-12
WO2007142986A2 (en) 2007-12-13
CL2007001542A1 (es) 2008-03-14
TW201107337A (en) 2011-03-01
EP2044101B1 (en) 2013-10-09
CA2650133A1 (en) 2007-12-13
TW200811189A (en) 2008-03-01
EP2322536A2 (en) 2011-05-18
AU2007255025B2 (en) 2011-07-14
KR101061658B1 (ko) 2011-09-01
DK2044101T3 (da) 2014-01-13
PL2044101T3 (pl) 2014-03-31
MA30485B1 (fr) 2009-06-01
WO2007142986A3 (en) 2008-04-10
US7851439B2 (en) 2010-12-14
PE20121011A1 (es) 2012-08-25
AU2007255025A1 (en) 2007-12-13
US20080221142A1 (en) 2008-09-11
CR10430A (es) 2009-01-15
SI2044101T1 (sl) 2014-01-31
CN102399260B (zh) 2015-04-15
KR20090006869A (ko) 2009-01-15
IL194880A0 (en) 2011-08-01
TNSN08496A1 (en) 2010-04-14
PT2044101E (pt) 2014-01-03
US20100267757A1 (en) 2010-10-21
TWI342310B (en) 2011-05-21
RU2450015C2 (ru) 2012-05-10
EP2044101A2 (en) 2009-04-08
AR060977A1 (es) 2008-07-23
UA95627C2 (ru) 2011-08-25
PE20080103A1 (es) 2008-04-03
JP5351014B2 (ja) 2013-11-27
CN101454337A (zh) 2009-06-10
NZ572154A (en) 2011-12-22
ECSP088922A (es) 2008-12-30
ES2441993T3 (es) 2014-02-07

Similar Documents

Publication Publication Date Title
NO20084749L (no) Organiske forbindelser og deres anvendelser
NO20082753L (no) Transdermalt terapeutisk system
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
PL2231636T3 (pl) Pochodne pirazolowe i ich zastosowanie jako inhibitorów kinaz zależnych od cyklin
NO20081042L (no) PPAR aktive forbindelser
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
WO2009031040A3 (en) Compounds with anti-cancer activity
NO20090880L (no) Banumsulfatinneholdende kompositt
SI1827441T1 (sl) Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
NO20081838L (no) 5-lipoksygenaseaktiverende protein-(FLAP)-inhibitorer
BRPI0817871A2 (pt) Aparelho para controle de fluxo em um órgão do corpo.
ATE526375T1 (de) Korrosionshemmende beschichtungszusammensetzung auf basis waesseriger dispersionen, umfassend ein organisches titanat und/oder zirkonat
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
NO20084850L (no) MGLUR5 modulatorer I
EA201101477A1 (ru) Органические соединения и их применение
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
NO20085029L (no) Substituerte pyridylamidforbindelser som modulatorer av histamin H3 reseptoren
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
TNSN08496A1 (en) Aminothiazoles and their uses
BRPI0816952A2 (pt) Composição para tratar ou contralar uma infecção em um indivíduo, e, usos de uma fluoroquinolona e de uma combinação
BRPI0817472A2 (pt) Composição, métodos para tratamento adjuntivo farmacológico, para controlar ou prevenir progressão de glaucoma em um indivíduo, e para fabricar uma composição
WO2008051523A3 (en) Carbazole derivatives useful as medicaments in cancer therapy